Hanes D

No ORCID on file · 2 papers in corpus

nonrandomized-trial 2022

Safety and tolerability of Pau d' Arco (Tabebuia avellanedae) for primary dysmenorrhea: A single-arm, open-label trial on adults ages 18-45

Advances in integrative medicine ·doi:10.1016/j.aimed.2022.04.003

OBJECTIVES: To evaluate the safety and tolerability of encapsulated Tabebuia avellanedae in generally healthy women aged 18-45 with primary dysmenorrhea. METHODS: A single arm, open-label trial was conducted in which 1050 mg/day of encapsu…

nonrandomized-trial 2020

Early evidence of efficacy for orally administered SPM-enriched marine lipid fraction on quality of life and pain in a sample of adults with chronic pain

Journal of translational medicine ·doi:10.1186/s12967-020-02569-5

BACKGROUND: Marine lipids contain omega-3 fatty acids that can be metabolized into anti-inflammatory and pro-resolving mediators-namely 17-HDHA and 18-HEPE-which can serve as modulators of the pain experience. The purpose of this study was …